Aurobindo Pharma informs about disclosure

10 Nov 2021 Evaluate

Aurobindo Pharma has informed that the company has received a communication from the USFDA classifying the inspection conducted at its Unit I (API) manufacturing facility in Hyderabad, India between August 2 to August 12, 2021 as Official Action Indicated (OAI), keeping the status unchanged. The Company believes that this inspection classification will not impact the continuing commercial supplies to the US market from this facility. The Company will be engaging with the regulator and is fully committed in resolving the status of this facility at the earliest. This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.


Aurobindo Pharma Share Price

1194.00 43.45 (3.78%)
30-Jan-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1215.70
Cipla 1323.95
Zydus Lifesciences 888.50
Lupin 2150.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×